Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

After obtaining formal institutional review board approval, the charts of 441 patients from 1996 to 2005 receiving low-dose-rate brachytherapy for prostate ... to offer androgen ablation was ...

A report into recurrent prostate cancer by Figg et al ... time to PSA progression seems to occur after two courses of androgen ablation, which might correspond to the time for the evolution ...

In a Maple Grove industrial strip mall unequipped with the beanbag chairs common to Silicon Valley startups, Francis Medical ...

“A standard approach for patients with metastatic prostate cancer has been to give drugs that target the androgen receptor, and then if that fails, to give chemotherapy,” Dr. Morris explains. “But ...

The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens (hormones responsible for developing male characteristics) bind to the androgen receptor ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

In many cases prostate cancer develops slowly, although in some cases it can be aggressive and metastasize to other parts of the body. Although resistance develops in response to androgen receptor ...

Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...